When pooled analysis was performed for RCTs that included only diabetic patients, SGLT-2 inhibitors reduced the risk of a composite of hospitalization for HF and CV death (HR [95 % CI] = 0.75 [0.62, 0.91], Pfix = 0.003; heterogeneity, P = 0.33, I2 = 12 %) but not the risk of all-cause death (OR [95 % CI] = 1.05 [0.77, 1.43], Pfix = 0.78 heterogeneity, P = 0.84, I2 = 0 %; supplemental Fig. 3). Here, SLC5A2 is linked to hydrops fetalis.